AEON — Aeon Biopharma Share News
0.000.00%
Last trade - 00:00Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition
Brief: Aeon Biopharma Approves 1-For-72 Reverse Stock Split
Brief: Aeon Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards
Brief: Aeon Biopharma, Inc. Announces Pricing Of Approximately $20.0 Million Underwritten Public Offering
Brief: Aeon Biopharma Announces Positive Outcome From FDA Biosimilar Advisory Meeting
Brief: Aeon Biopharma Files For Class A Common Stock Offering Of Up To $50.0 Million
Brief: AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
Brief: AEON Biopharma Announces Termination Of Peter Reynolds As CFO
AEON Biopharma falls as drug to prevent migraine fails study
Brief: Aeon Biopharma Announces $15 Million Financing Transaction And Termination Of Forward Purchase Agreements
Brief: Aeon Biopharma Announces Clinical Update And Productive End-Of-Phase 2 Meeting With FDA On Abp-450 (Prabotulinumtoxina) For The Preventive Treatment Of Migraine
Brief: AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD
Brief: Aeon Biopharma Announces Topline Results From Phase 2 Trial Of Abp-450 (Prabotulinumtoxina) For The Preventive Treatment Of Episodic Migraine
Brief: Aeon Biopharma Presents Positive Results From Phase 2 Clinical Trial Of Abp-450 In Cervical Dystonia
Brief: Priveterra Acquisition Corp Announces Completion Of Business Combination With AEON Biopharma
Brief: Priveterra Acquisition Announces Authorization To List On NYSE Upon Completion Of Business Combination With Aeon Biopharma